Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy

MLA

Paola Cravero, et al. “Brigatinib in the First-Line Treatment of ALK+ Metastatic NSCLC: Safety and Efficacy.” Expert Review of Anticancer Therapy, vol. 21, no. 8, Apr. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0c5cdb02179107aa5e2a1464db208b53&authtype=sso&custid=ns315887.

APA

Paola Cravero, Lucio Crinò, Marco Angelo Burgio, Giuseppe Bronte, Kalliopi Andrikou, Ilaria Priano, Alessandro Cafaro, Luigi Pasini, & Angelo Delmonte. (2021). Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy. Expert Review of Anticancer Therapy, 21(8).

Chicago

Paola Cravero, Lucio Crinò, Marco Angelo Burgio, Giuseppe Bronte, Kalliopi Andrikou, Ilaria Priano, Alessandro Cafaro, Luigi Pasini, and Angelo Delmonte. 2021. “Brigatinib in the First-Line Treatment of ALK+ Metastatic NSCLC: Safety and Efficacy.” Expert Review of Anticancer Therapy 21 (8). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0c5cdb02179107aa5e2a1464db208b53&authtype=sso&custid=ns315887.